Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, ...
N.V. and Partner Therapeutics, Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has ...
The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...
Monday announced an agreement with Partner Therapeutics, Inc. to commercialize Zenocutuzumab for the treatment of ...
Event: Piper Sandler 36th Annual Healthcare Conference Location: The Lotte New York Palace, NY Presentation: Thursday, December 5, 8:00 a.m. EST Webcast: https://event.webcasts.com/ A replay will be ...
Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc ...
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – ...
The NRG1 gene encodes neuregulin (also known as heregulin), the ligand for HER3. Fusions between NRG1 and partner genes are ...
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...
Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...
The health department sent "letters of intent" to the group, but the move sets up what could be lengthy litigation from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback